• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鼻持续气道正压通气联合早期表面活性剂治疗小于30周胎龄新生儿呼吸窘迫综合征

Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation.

作者信息

Verder H, Albertsen P, Ebbesen F, Greisen G, Robertson B, Bertelsen A, Agertoft L, Djernes B, Nathan E, Reinholdt J

机构信息

Departments of Pediatrics, Holbaek Central Hospital, Denmark.

出版信息

Pediatrics. 1999 Feb;103(2):E24. doi: 10.1542/peds.103.2.e24.

DOI:10.1542/peds.103.2.e24
PMID:9925870
Abstract

OBJECTIVE

To determine whether early versus late treatment with porcine surfactant (Curosurf) reduces the requirement of mechanical ventilation in very preterm infants primarily supported by nasal continuous positive airway pressure (nasal CPAP).

DESIGN

Multicenter randomized, controlled trial.

PATIENTS

The study population comprised 60 infants <30 weeks' gestation with respiratory distress syndrome (RDS) who had an arterial to alveolar oxygen tension ratio (a/APO2) of 0.35 to 0.22. The cohort from which the study population was generated comprised 397 infants.

RESULTS

The need for mechanical ventilation or death within 7 days of age was reduced from 63% in the late-treated infants to 21% in early-treated infants. Increasing numbers of antenatal steroid doses also improved the outcome, especially in the early-treated infants. Six hours after randomization mean a/APO2 rose to 0.48 in the early-treated infants compared with 0.36 in the late-treated. The need of mechanical ventilation before discharge was reduced from 68% in the late-treated to 25% in the early-treated infants.

CONCLUSIONS

Nasal CPAP in combination with early treatment with Curosurf significantly improves oxygenation and reduces the subsequent need for mechanical ventilation in infants <30 weeks' gestational age with RDS.

摘要

目的

确定猪肺表面活性物质(珂立苏)早期治疗与晚期治疗相比,是否能降低主要依靠经鼻持续气道正压通气(经鼻CPAP)支持的极早产儿机械通气的需求。

设计

多中心随机对照试验。

患者

研究人群包括60例孕周<30周、患有呼吸窘迫综合征(RDS)且动脉血氧分压与肺泡血氧分压比值(a/APO2)为0.35至0.22的婴儿。产生研究人群的队列包括397例婴儿。

结果

7日龄内机械通气需求或死亡发生率从晚期治疗组婴儿的63%降至早期治疗组婴儿的21%。产前使用类固醇剂量增加也改善了结局,尤其是在早期治疗组婴儿中。随机分组6小时后,早期治疗组婴儿的平均a/APO2升至0.48,而晚期治疗组为0.36。出院前机械通气需求从晚期治疗组的68%降至早期治疗组的25%。

结论

经鼻CPAP联合早期使用珂立苏治疗可显著改善<30周胎龄RDS婴儿的氧合,并降低其随后对机械通气的需求。

相似文献

1
Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation.鼻持续气道正压通气联合早期表面活性剂治疗小于30周胎龄新生儿呼吸窘迫综合征
Pediatrics. 1999 Feb;103(2):E24. doi: 10.1542/peds.103.2.e24.
2
Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish-Swedish Multicenter Study Group.表面活性剂治疗和经鼻持续气道正压通气用于新生儿呼吸窘迫综合征。丹麦-瑞典多中心研究组。
N Engl J Med. 1994 Oct 20;331(16):1051-5. doi: 10.1056/NEJM199410203311603.
3
Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for RDS.对于患有呼吸窘迫综合征(RDS)或有RDS风险的早产儿,早期给予表面活性剂并进行短暂通气与选择性给予表面活性剂及持续机械通气的比较。
Cochrane Database Syst Rev. 2002(2):CD003063. doi: 10.1002/14651858.CD003063.
4
Very early surfactant without mandatory ventilation in premature infants treated with early continuous positive airway pressure: a randomized, controlled trial.极早早产儿在接受早期持续气道正压通气治疗时不进行强制通气使用表面活性剂:一项随机对照试验。
Pediatrics. 2009 Jan;123(1):137-42. doi: 10.1542/peds.2007-3501.
5
Nasal intermittent positive pressure ventilation after surfactant treatment for respiratory distress syndrome in preterm infants <30 weeks' gestation: a randomized, controlled trial.经表面活性物质治疗的早产儿呼吸窘迫综合征(胎龄<30 周)行鼻间歇正压通气:一项随机对照试验。
J Perinatol. 2012 May;32(5):336-43. doi: 10.1038/jp.2012.1. Epub 2012 Feb 2.
6
[Early selective surfactant treatment--also to very premature infants treated with CPAP?].[早期选择性表面活性剂治疗——也适用于接受持续气道正压通气治疗的极早产儿?]
Ugeskr Laeger. 2001 Dec 10;163(50):7053-6.
7
Efficacy of a new technique - INtubate-RECruit-SURfactant-Extubate - "IN-REC-SUR-E" - in preterm neonates with respiratory distress syndrome: study protocol for a randomized controlled trial.一种新技术——插管-复张-表面活性剂-拔管(“IN-REC-SUR-E”)用于呼吸窘迫综合征早产儿的疗效:一项随机对照试验的研究方案
Trials. 2016 Aug 18;17:414. doi: 10.1186/s13063-016-1498-7.
8
Is there a necessity for multiple doses of surfactant for respiratory distress syndrome of premature infants?对于早产儿呼吸窘迫综合征,是否有必要多次使用表面活性剂?
Turk J Pediatr. 2012 Jul-Aug;54(4):368-75.
9
Early versus late surfactant treatment in preterm infants of 27 to 32 weeks' gestational age: a multicenter controlled clinical trial.
Pediatrics. 1998 Nov;102(5):1153-60. doi: 10.1542/peds.102.5.1153.
10
Early rescue administration of surfactant and nasal continuous positive airway pressure in preterm infants <32 weeks gestation.早产儿(胎龄<32 周)早期应用表面活性物质和经鼻持续气道正压通气治疗。
Indian Pediatr. 2011 Aug;48(8):601-5. doi: 10.1007/s13312-011-0104-z. Epub 2010 Nov 30.

引用本文的文献

1
Decreasing early invasive mechanical ventilation exposure in preterm infants: a quality improvement initiative.减少早产儿早期有创机械通气暴露:一项质量改进举措。
J Perinatol. 2025 Jan;45(1):149-156. doi: 10.1038/s41372-024-02098-9. Epub 2024 Aug 28.
2
Curosurf surfactant application on preterm babies with respiratory complications-health-economic benefits.珂立苏表面活性物质在伴有呼吸并发症的早产儿中的应用-健康经济效益。
Afr Health Sci. 2024 Mar;24(1):220-227. doi: 10.4314/ahs.v24i1.27.
3
To intubate or not to intubate, is that the question?
是否进行插管,这是个问题吗?
Pediatr Res. 2024 Jun;95(7):1685-1687. doi: 10.1038/s41390-024-03073-y. Epub 2024 Feb 10.
4
Effect of Nasal Continuous Airway Pressure With and Without Surfactant Administration for the Treatment of Respiratory Distress Syndrome in Preterm Neonates.经鼻持续气道正压通气联合或不联合表面活性剂治疗早产儿呼吸窘迫综合征的效果
Cureus. 2023 Oct 13;15(10):e46974. doi: 10.7759/cureus.46974. eCollection 2023 Oct.
5
Clinical decision thresholds for surfactant administration in preterm infants: a systematic review and network meta-analysis.早产儿表面活性剂给药的临床决策阈值:一项系统评价和网状荟萃分析。
EClinicalMedicine. 2023 Jul 20;62:102097. doi: 10.1016/j.eclinm.2023.102097. eCollection 2023 Aug.
6
Health Economic Studies of Surfactant Replacement Therapy in Neonates with Respiratory Distress Syndrome: A Systematic Literature Review.新生儿呼吸窘迫综合征表面活性剂替代疗法的卫生经济学研究:一项系统文献综述
Pharmacoecon Open. 2023 May;7(3):359-371. doi: 10.1007/s41669-023-00399-x. Epub 2023 Mar 11.
7
European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update.欧洲呼吸窘迫综合征管理共识指南:2022 年更新版。
Neonatology. 2023;120(1):3-23. doi: 10.1159/000528914. Epub 2023 Feb 15.
8
Health Economics of Selective Early Rescue Surfactant Administration and Standard Surfactant Administration for Newborns With Respiratory Distress Syndrome.选择性早期给予救援性表面活性剂与标准表面活性剂治疗新生儿呼吸窘迫综合征的卫生经济学
J Pediatr Pharmacol Ther. 2022;27(8):695-702. doi: 10.5863/1551-6776-27.8.695. Epub 2022 Nov 17.
9
Overview of the neonatal research network: History, contributions, challenges, and future.新生儿研究网络概述:历史、贡献、挑战与未来。
Semin Perinatol. 2022 Nov;46(7):151634. doi: 10.1016/j.semperi.2022.151634. Epub 2022 Jun 10.
10
Techniques to evaluate surfactant activity for a personalized therapy of RDS neonates.评估表面活性剂活性以用于 RDS 新生儿个体化治疗的技术。
Biomed J. 2021 Dec;44(6):671-677. doi: 10.1016/j.bj.2021.11.001. Epub 2021 Nov 7.